Should you buy Gossamer Bio stock now?
No, the technical signal for Gossamer Bio is currently SELL. Gossamer Bio trades at $0.00 as of 8/28/2026. The overall technical signal is: Sell. The technical analysis shows the following: MACD is negative (bearish trend) at 0.000 with rising momentum (signal: -0.002); RSI is at 49.8 (neutral zone). This is a technical observation based on current data, not investment advice.
What is the price target for Gossamer Bio stock?
There is currently no active analyst price target for Gossamer Bio.
Is Gossamer Bio a dividend stock?
No, Gossamer Bio does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Gossamer Bio stock?
Gossamer Bio is rated as a stock in the risk category Conservative. the annual standard deviation is 0.0%, which classifies the stock as Conservative.
Is Gossamer Bio overvalued?
Gossamer Bio has the following valuation ratios: a P/S ratio of 1.6, a P/B ratio of 8.1.
Is Gossamer Bio overbought?
No, Gossamer Bio is not overbought. RSI is at 49.8 (neutral zone). The technical indicators show: RSI is at 49.8 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Gossamer Bio earnings report?
The date of the next earnings report for Gossamer Bio has not been published yet. Check the company's investor calendar for updates.
Is Gossamer Bio shorted?
Yes, Gossamer Bio is shorted with 18.0% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Gossamer Bio stock?
Yes, insiders are net buyers of Gossamer Bio – they are buying more shares than they are selling. Across the last 20 reported transactions, the split is 13 purchases and 7 sales, with a net 2,615,746 $ bought. Active buyers include Milligan Sandra, Hasnain Faheem, Giraudo Bryan and others. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Gossamer Bio a good stock?
Based on our total score, Gossamer Bio is rated as a poor stock with a total score of 24 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 24/100. In addition: technical signal: Sell. Whether Gossamer Bio is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Gossamer Bio stock?
The outlook for Gossamer Bio based on current data: Detailed data is currently not available. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Gossamer Bio stock moving?
Gossamer Bio is moving right now. The technical indicators show: short interest is 18.0% (high – many are betting on a decline); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Gossamer Bio go?
There is currently no active analyst price target for Gossamer Bio. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Gossamer Bio fall?
We lack enough history to give a specific floor for Gossamer Bio. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Gossamer Bio do?
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, p... The company belongs to the Healthcare sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Gossamer Bio as an investment.
Did Gossamer Bio raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Gossamer Bio. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Gossamer Bio making money or losing money?
No, Gossamer Bio is currently not making money — the company is losing money with a negative profit margin of -235.0%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Gossamer Bio go bankrupt?
The bankruptcy risk of Gossamer Bio is rated as elevated. Altman Z2 (a model for assessing financial distress) is -86.40 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 969% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Gossamer Bio have a lot of debt?
Yes, Gossamer Bio has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 969%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.